Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> MutationBella Kaufman, Susan M. Domchek, Ronnie Shapira‐Frommer et al.|Journal of Clinical Oncology|2014Cited by 1.7k
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M. Domchek, Bella Kaufman, Carol Aghajanian et al.|Gynecologic Oncology|2015Cited by 300
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJonathan A. Ledermann, Anna Fagotti, Susana Banerjee et al.|Annals of Oncology|2024Cited by 277
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancerPanagiotis A. Konstantinopoulos, Ronnie Shapira‐Frommer, Jungmin Lee et al.|Gynecologic Oncology|2022Cited by 66
20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)Domenica Lorusso, V. Makker, N. Colombo et al.|Annals of Oncology|2022Cited by 1